Abeona Therapeutics Inc
NASDAQ:ABEO
| Market Cap (Intraday) | 314.09M |
| Current PE | 5.49 |
| Forward PE | 5.64 |
| 2yr Forward PE | 214.33 |
| 10-Day MA | $6.72 |
| 50-Day MA | $6.57 |
| 200-Day MA | $5.86 |
Abeona Therapeutics Inc Stock, NASDAQ:ABEO
6555 Carnegie Avenue, 4th floor, Cleveland, Ohio 44103
United States of America
Phone: +1.646.813.4701
Number of Employees: 84
Description
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.